MCID: PNC008
MIFTS: 40

Pancreatic Endocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 14 69
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 41
Islet Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD10 32 C25.4
ICD9CM 34 157.4
MeSH 41 D018273
NCIt 46 C3770
UMLS 69 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to somatostatinoma and islet cell tumor. An important gene associated with Pancreatic Endocrine Carcinoma is SSTR2 (Somatostatin Receptor 2), and among its related pathways/superpathways is Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and endothelial, and related phenotype is behavior/neurological.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 somatostatinoma 11.5
2 islet cell tumor 11.1
3 pancreatic islet cell tumors 11.1
4 pancreatitis 10.3
5 type c thymoma 10.2 SST SSTR2
6 hormone producing pituitary cancer 10.2 SST SSTR2
7 pituitary carcinoma 10.2 SST SSTR2
8 esophageal neuroendocrine tumor 10.2 NCAM1 SYP
9 ovarian large-cell neuroendocrine carcinoma 10.2 NCAM1 SYP
10 lung combined type small cell carcinoma 10.2 NCAM1 SYP
11 malignant glandular tumor of peripheral nerve sheath 10.2 SST SYP
12 adenoma of the pancreas 10.2 SST SYP
13 olfactory neuroblastoma 10.2 SSTR2 SYP
14 cutaneous ganglioneuroma 10.2 NCAM1 SYP
15 gallbladder small cell carcinoma 10.2 NCAM1 SYP
16 pancreatic somatostatinoma 10.2 SST SYP
17 extrahepatic bile duct adenocarcinoma 10.2 NCAM1 SYP
18 orbital cancer 10.2 NCAM1 SYP
19 hypoganglionosis 10.2 NCAM1 SYP
20 pancreatic serous cystadenoma 10.2 NCAM1 SYP
21 conventional angiosarcoma 10.2 NCAM1 SYP
22 growth hormone secreting pituitary adenoma 10.2 SST SSTR2
23 supratentorial primitive neuroectodermal tumor 10.2 NCAM1 SYP
24 endometrial small cell carcinoma 10.2 NCAM1 SYP
25 mediastinal cancer 10.2 NCAM1 SYP
26 subependymoma 10.2 NCAM1 SYP
27 angiomyoma 10.2 NCAM1 SYP
28 gastric squamous cell carcinoma 10.2 NCAM1 SYP
29 gastric small cell carcinoma 10.2 NCAM1 SYP
30 pancreatoblastoma 10.1 SST SYP
31 small cell neuroendocrine carcinoma 10.1 NCAM1 SYP
32 cervical clear cell adenocarcinoma 10.1 NCAM1 SYP
33 spermatocele 10.1 NCAM1 SYP
34 functional colonic disease 10.1 SST SYP
35 binswanger's disease 10.1 SST SYP
36 carcinoid syndrome 10.1 SST SYP
37 cervix small cell carcinoma 10.1 NCAM1 SYP
38 duodenum cancer 10.1 SST SYP
39 orbital plasma cell granuloma 10.1 NCAM1 SST
40 pancreatic gastrinoma 10.1 SST SYP
41 large cell neuroendocrine carcinoma 10.1 NCAM1 SYP
42 ectopic cushing syndrome 10.1 SST SYP
43 adrenal rest tumor 10.1 NCAM1 SYP
44 colonic pseudo-obstruction 10.1 SST SYP
45 ganglioneuroma 10.1 NCAM1 SYP
46 lung benign neoplasm 10.0 NCAM1 SYP
47 organ system benign neoplasm 10.0 SST SYP
48 primary pigmented nodular adrenocortical disease 10.0 NCAM1 SYP
49 small cell carcinoma 10.0 NCAM1 SYP
50 peripheral nervous system neoplasm 10.0 NCAM1 SYP

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

MGI Mouse Phenotypes related to Pancreatic Endocrine Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.02 FOXK1 NCAM1 SST SSTR2 SYP

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
4
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
5
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
9 Pancreatic Polypeptide Investigational Phase 2, Phase 3, Phase 1 59763-91-6
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Antimetabolites Phase 2, Phase 3,Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
14 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
15 Hormone Antagonists Phase 2, Phase 3,Phase 1
16 Hormones Phase 2, Phase 3,Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
18 Adjuvants, Anesthesia Phase 3
19 Analgesics Phase 3
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Central Nervous System Depressants Phase 3
25 Liver Extracts Phase 3,Phase 2,Phase 1
26 Narcotics Phase 3
27 Peripheral Nervous System Agents Phase 3
28 Folate Nutraceutical Phase 2, Phase 3
29 Vitamin B9 Nutraceutical Phase 2, Phase 3
30 Cola Nutraceutical Phase 3,Phase 2,Phase 1
31
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
33
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
34
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
35
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
36
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
37
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
40
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
41
Pancrelipase Approved, Investigational Phase 2 53608-75-6
42
Melphalan Approved Phase 2 148-82-3 460612 4053
43
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
44
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
nivolumab Approved Phase 2 946414-94-4
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 52)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
5 A Study of IMC-A12 in Islet Cell Cancer Completed NCT00781911 Phase 2 depot octreotide
6 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
7 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
8 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
9 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT01169649 Phase 2 MK-2206
10 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
11 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
12 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
13 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
14 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
15 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
16 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
17 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
20 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
21 Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Recruiting NCT02820857 Phase 2 Folfiri-bevacizumab;Folfiri
22 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
23 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Recruiting NCT02893930 Phase 2 Sapanisertib
24 FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Recruiting NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
25 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
28 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting NCT02101918 Phase 2
29 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
30 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
31 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
32 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
33 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
34 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
35 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
36 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
37 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
38 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
39 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
40 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
41 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
42 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
43 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
44 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
45 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
46 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
47 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
48 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene Completed NCT00444795 Sunitinib malate;Sunitinib malate;sunitinib malate
49 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220 sunitinib
50 Clinical Evaluation of i-STAT Analyzer Recruiting NCT02897154

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

38
Pancreas, Liver, Endothelial, Breast, Kidney, Bone

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show all 17)
# Title Authors Year
1
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
2
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
3
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. ( 21868544 )
2011
4
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
5
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008
6
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
7
Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. ( 17629086 )
2007
8
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. ( 17158766 )
2006
9
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. ( 16364959 )
2006
10
Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report. ( 15849491 )
2005
11
Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. ( 15920550 )
2005
12
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? ( 14962717 )
2004
13
Curative resection for a pancreatic endocrine carcinoma involving the portal vein. ( 15532841 )
2004
14
Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. ( 11964045 )
2002
15
Pancreatic endocrine carcinoma with multiple hormone production in a raccoon (Procyon lotor). ( 10213674 )
1999
16
Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. ( 1322859 )
1992
17
Pancreatic endocrine carcinoma with ectopic PTH-production and paraneoplastic hypercalcaemia. ( 3082066 )
1986

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.52 NCAM1 SYP

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.8 SSTR2 SSTR5 SYP

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.43 SST SSTR2 SSTR5
2 response to nutrient GO:0007584 9.37 SST SSTR2
3 digestion GO:0007586 9.32 SST SSTR2
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.16 SSTR2 SSTR5
5 cellular response to glucocorticoid stimulus GO:0071385 8.96 SSTR2 SSTR5
6 somatostatin signaling pathway GO:0038170 8.62 SSTR2 SSTR5

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 8.96 SSTR2 SSTR5
2 somatostatin receptor activity GO:0004994 8.62 SSTR2 SSTR5

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....